Overview

* Puma Q3 2025 product revenue declines to $51.9 mln from $56.1 mln in Q3 2024

* Puma Biotechnology ( PBYI ) reports Adjusted EPS of $0.21

* Company raises full-year 2025 NERLYNX revenue and net income estimates

Outlook

* Puma raises 2025 net product revenue forecast to $198-$200 mln

* Company increases 2025 net income estimate to $27-$29 mln

* Puma anticipates key clinical milestones for alisertib in H1 2026

Result Drivers

* U.S. SALES INCREASE - Co reports 8% increase in bottles of NERLYNX sold in U.S. market, contributing to higher net selling price

* OPERATING COSTS DECREASE - Total operating costs and expenses decreased significantly, aiding earnings trend

* INCREASED DEMAND - CEO attributes positive earnings trend to increased demand for NERLYNX

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $51.90

Product mln

Revenue

Q3 $0.21

Adjusted

EPS

Q3 EPS $0.18

Q3 $10.50

Adjusted mln

Net

Income

Q3 Net $8.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Puma Biotechnology Inc ( PBYI ) is $4.00, about 23.6% below its November 5 closing price of $4.95

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)